These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22352370)

  • 1. Pharmacokinetics of 250 μg anti-D IgG in the third trimester of pregnancy: an observational study.
    Tiblad E; Wikman A; Rane A; Jansson Y; Westgren M
    Acta Obstet Gynecol Scand; 2012 May; 91(5):587-92. PubMed ID: 22352370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of anti-D IgG in pregnant RhD-negative women.
    Bichler J; Schöndorfer G; Pabst G; Andresen I
    BJOG; 2003 Jan; 110(1):39-45. PubMed ID: 12504934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin.
    MacKenzie IZ; Roseman F; Findlay J; Thompson K; Jackson E; Scott J; Reed M
    BJOG; 2006 Jan; 113(1):97-101. PubMed ID: 16398777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
    Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT
    Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen.
    Chaffe B; Ford J; Bills V
    Transfus Med; 2007 Oct; 17(5):399-403. PubMed ID: 17903141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
    Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
    Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine antenatal anti-D prophylaxis--is the protection adequate?
    Davies J; Chant R; Simpson S; Powell R
    Transfus Med; 2011 Dec; 21(6):421-6. PubMed ID: 21906191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postdelivery levels of anti-D IgG prophylaxis in D- mothers depend on maternal body weight.
    Woelfer B; Schuchter K; Janisiw M; Hafner E; Philipp K; Panzer S
    Transfusion; 2004 Apr; 44(4):512-7. PubMed ID: 15043566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy.
    Okwundu CI; Afolabi BB
    Cochrane Database Syst Rev; 2013 Jan; (1):CD007885. PubMed ID: 23440818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK.
    Jilma-Stohlawetz P; Reiter RA; Panzer S; Horvath M; Eppel W; Jilma B
    Transfus Apher Sci; 2005 Oct; 33(2):135-40. PubMed ID: 16112906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guideline for prevention of RhD alloimmunizationin RhD negative women].
    Lubušký M; Procházka M; Simetka O; Holusková I
    Ceska Gynekol; 2013 Apr; 78(2):132-3. PubMed ID: 23710977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers.
    Bichler J; Spycher MO; Amstutz HP; Andresen I; Gaede K; Miescher S
    Transfus Med; 2004 Apr; 14(2):165-71. PubMed ID: 15113381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Spontaneous antepartal RhD alloimmunization].
    Studničková M; Holusková I; Durdová V; Kratochvílová T; Strašilová P; Marková I; Lubušký M
    Ceska Gynekol; 2015 Dec; 80(6):401-4. PubMed ID: 26741153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse effects and patient information].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S112-1S118. PubMed ID: 16495836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Following targeted routine antenatal anti-D prophylaxis, almost half of the pregnant women had undetectable anti-D prophylaxis at delivery.
    Sørensen K; Stjern HE; Karlsen BAG; Tomter G; Ystad I; Herud I; Baevre MS; Llohn AH; Akkök ÇA
    Acta Obstet Gynecol Scand; 2022 Apr; 101(4):431-440. PubMed ID: 35224728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The scientific basis of antenatal prophylaxis.
    Urbaniak SJ
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():11-8. PubMed ID: 9863973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years.
    MacKenzie IZ; Findlay J; Thompson K; Roseman F
    BJOG; 2006 Jul; 113(7):839-43. PubMed ID: 16827770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients.
    Ben-David G; Sheiner E; Levy A; Erez O; Mazor M
    J Matern Fetal Neonatal Med; 2008 Apr; 21(4):255-9. PubMed ID: 18330822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.